BioVie Inc. (BIVI) Income Statement Analysis

See more : Taihei Dengyo Kaisha, Ltd. (1968.T) Income Statement Analysis – Financial Results

Complete financial analysis of BioVie Inc. (BIVI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BioVie Inc., a leading company in the Biotechnology industry within the Healthcare sector.

You may be interested

Plastiques du Val de Loire (PVL.PA) Income Statement Analysis – Financial Results
Altius Renewable Royalties Corp. (ARR.TO) Income Statement Analysis – Financial Results
Foxtons Group plc (FOXT.L) Income Statement Analysis – Financial Results
Panchsheel Organics Limited (PANCHSHEEL.BO) Income Statement Analysis – Financial Results
Jagran Prakashan Limited (JAGRAN.BO) Income Statement Analysis – Financial Results

BioVie Inc. (BIVI)

Industry: Biotechnology

Sector: Healthcare

Website: https://bioviepharma.com

About BioVie Inc.

BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is based in Carson City, Nevada.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013
Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cost of Revenue	229.38K	266.84K	237.42K	229.38K	229.38K	229.38K	229.38K	229.38K	51.04K	0.00	0.00	0.00
Gross Profit	-229.38K	-266.84K	-237.42K	-229.38K	-229.38K	-229.38K	-229.38K	-229.38K	-51.04K	0.00	0.00	0.00
Gross Profit Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Research & Development	23.10M	33.30M	17.26M	133.19M	1.15M	1.01M	370.85K	466.35K	37.90K	4.20K	49.42K	0.00
General & Administrative	0.00	0.00	0.00	0.00	0.00	1.26M	1.77M	857.88K	343.09K	229.18K	272.97K	0.00
Selling & Marketing	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	8.85M	11.55M	9.77M	4.64M	1.31M	1.26M	1.77M	857.88K	343.09K	229.18K	272.97K	70.06K
Other Expenses	0.00	229.38M	229.38K	229.38K	229.38K	229.38K	229.38K	229.38K	51.04K	212.71K	247.08K	0.00
Operating Expenses	31.95M	45.08M	27.25M	138.05M	2.69M	2.50M	2.37M	1.55M	432.03K	233.38K	322.39K	70.06K
Cost & Expenses	32.18M	45.08M	27.25M	138.05M	2.69M	2.50M	2.37M	1.55M	432.03K	233.38K	322.39K	70.06K
Interest Income	1.14M	562.26K	44.08K	21.97K	234.00	1.16K	4.00	14.00	186.00	369.00	489.00	20.00
Interest Expense	2.89M	4.30M	2.16M	559.46K	4.77M	273.00	40.96K	0.00	81.00	0.00	0.00	0.00
Depreciation & Amortization	229.38K	266.84K	237.42K	229.38K	229.38K	229.38K	229.38K	229.38K	51.04K	369.00	489.00	70.06K
EBITDA	-31.95M	-45.69M	-23.68M	-137.80M	-2.46M	-2.27M	-2.14M	-1.32M	-380.81K	-233.01K	-321.90K	20.00
EBITDA Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Income	-32.18M	-45.08M	-27.25M	-138.05M	-2.69M	-2.50M	-2.37M	-1.55M	-432.03K	-233.38K	-322.39K	-70.06K
Operating Income Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Total Other Income/Expenses	59.05K	-5.18M	1.17M	7.80M	-13.98M	52.29K	-40.96K	222.94K	105.00	369.00	489.00	20.00
Income Before Tax	-32.12M	-50.26M	-26.08M	-130.25M	-16.68M	-2.44M	-2.41M	-1.33M	-431.92K	-233.01K	-321.90K	-70.04K
Income Before Tax Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Income Tax Expense	0.00	4.30M	-3.29M	559.46K	4.77M	-51.40K	-1.00	-222.93K	-105.00	-369.00	-489.00	20.00
Net Income	-32.12M	-50.26M	-26.08M	-183.85M	-33.78M	-2.49M	-2.43M	-1.33M	-431.92K	-233.01K	-321.90K	-70.04K
Net Income Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EPS	-7.30	-15.47	-10.58	-148.23	-68.52	-9.82	-31.77	-18.61	-6.19	-3.34	-4.62	0.00
EPS Diluted	-7.30	-15.50	-10.60	-148.23	-68.52	-9.82	-31.77	-18.61	-6.19	-3.34	-4.62	0.00
Weighted Avg Shares Out	4.52M	3.24M	2.46M	1.24M	492.00K	253.00K	76.00K	71.00K	69.00K	69.00K	69.00K	32.98K
Weighted Avg Shares Out (Dil)	4.52M	3.25M	2.47M	1.24M	492.95K	253.96K	76.61K	71.51K	69.76K	69.77K	69.67K	32.98K

BioVie Inc. Class Action: Levi & Korsinsky Reminds BioVie Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 19, 2024 - BIVI

March 18, 2024accesswire.com

NEW YORK, NY / ACCESSWIRE / March 18, 2024 / If you suffered a loss on your BioVie Inc. (NASDAQ:BIVI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more...

Lost Money on BioVie Inc.(BIVI)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky

March 18, 2024accesswire.com

Shareholders that lost money on BioVie Inc.(BIVI) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More

March 17, 2024accesswire.com

NEW YORK, NY / ACCESSWIRE / March 17, 2024 / If you suffered a loss on your BioVie Inc. (NASDAQ:BIVI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more...

FINAL DEADLINE TOMORROW: The Schall Law Firm Encourages Investors in BioVie Inc. with Losses of $100,000 to Contact the Firm

March 17, 2024accesswire.com

LOS ANGELES, CA / ACCESSWIRE / March 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BioVie Inc. ("BioVie" or "the Company") (NASDAQ:BIVI) for violations of §§10(b) and...

1 2 3 4 5 6 7 8 9 10

Source: https://incomestatements.info
Category: Stock Reports

BioVie Inc. (BIVI) Income Statement Analysis – Financial Results

Leave a Reply Cancel reply

Recent Posts

Categories